Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of AR119982A1publicationCriticalpatent/AR119982A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La presente proporciona combinaciones que comprenden un anticuerpo o fragmento de unión a antígeno del mismo, por ejemplo, un anticuerpo monoclonal o un fragmento de unión a antígeno del mismo, que se une específicamente a ENTPD2 (por ejemplo, la proteína ENTPD2 humana), y un anticuerpo o fragmento de unión a antígeno del mismo, por ejemplo, un anticuerpo monoclonal o un fragmento de unión a antígeno del mismo, que se une específicamente a CD73 (por ejemplo, la proteína CD73 humana), y métodos de uso de tales combinaciones.The present provides combinations comprising an antibody or antigen-binding fragment thereof, eg, a monoclonal antibody or antigen-binding fragment thereof, that specifically binds to ENTPD2 (eg, the human ENTPD2 protein), and an antibody or antigen-binding fragment thereof, eg, a monoclonal antibody or antigen-binding fragment thereof, that specifically binds to CD73 (eg, the human CD73 protein), and methods of using such combinations .
ARP200102569A2019-09-182020-09-16
COMBINATION THERAPIES WITH ENTDPD2 ANTIBODIES
AR119982A1
(en)